Updating the Efficacy and Safety Experience of IL-17 Inhibitors

Dec 15, 2025

- Dec 14, 2026

0.75

Claim your AMA PRA Category 1 Credit(s), CNE Contact Hour(s) credit

Already have an Account? Log In
Don’t have an account? Register Today

Claim your Certificate

PCSK9 Inhibitors in Primary Prevention: A New Paradigm for Family Physicians

The Evolving Role of High Efficacy, Anti-CD40 Therapeutics for Relapsing Multiple Sclerosi...

Review of Biosimilar Therapeutics for Patients with Relapsing Multiple Sclerosis